HPS antioxidant trial

HPS antioxidant study, 2002	TRC3698
	download pdf: combination \| antioxydants for cardiovascular prevention

Treatments

Studied treatment	antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg -carotene daily)
Control treatment	matching placebo
Remarks	factorial design with cholesterol lowering therapy

Patients	UK adults (aged 40ďż˝80) with coronary disease, other occlusive arterial disease, or diabetes
Inclusion criteria	Men and women; aged about 40 years to 80 years; non-fasting blood total cholesterol concentrations of at least 3ďż˝5 mmol/L; substantial 5-year risk of death from coronary heart disease because of a past medical history of coronary heart disease, of other occlusive arterial disease, of diabetes mellitus, or of treated hypertension alone
Exclusion criteria	life-threatening conditions, such as chronic liver disease, severe renal disease, severe heart failure, severe chronic airways disease, or diagnosed cancer (other than non-melanoma skin cancer); high-dose vitamin E supplements

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Coronary event

1063 / 10269
1047 / 10267
1,02 [0,94;1,10]

stroke (fatal and non fatal)

511 / 10269
518 / 10267
0,99 [0,88;1,11]

Cardiovascular death

878 / 10269
840 / 10267
1,05 [0,95;1,14]

cardiovascular events

2306 / 10269
2312 / 10267
1,00 [0,95;1,05]

All cause death

1446 / 10269
1389 / 10267
1,04 [0,97;1,11]

Non fatal stroke

430 / 10269
435 / 10267
0,99 [0,87;1,13]

Non fatal MI

464 / 10269
467 / 10267
0,99 [0,88;1,13] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
Coronary event	1063 / 10269 (10,4%)	1047 / 10267 (10,2%)	1,02	[0,94;1,10]		2942
stroke (fatal and non fatal)	511 / 10269 (5,0%)	518 / 10267 (5,0%)	0,99	[0,88;1,11]		2942
Cardiovascular death	878 / 10269 (8,6%)	840 / 10267 (8,2%)	1,05	[0,95;1,14]		2942
cardiovascular events	2306 / 10269 (22,5%)	2312 / 10267 (22,5%)	1,00	[0,95;1,05]	fig 3	2942
All cause death	1446 / 10269 (14,1%)	1389 / 10267 (13,5%)	1,04	[0,97;1,11]		2942
Non fatal stroke	430 / 10269 (4,2%)	435 / 10267 (4,2%)	0,99	[0,87;1,13]		2942
Non fatal MI	464 / 10269 (4,5%)	467 / 10267 (4,5%)	0,99	[0,88;1,13]		2942
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 2942: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet 2002 Jul 6;360:23-33 0:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction (for a follow-up of jul 1994 - may 1997)
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
Coronary event	10,35%	10,20%	0,15%
stroke (fatal and non fatal)	4,98%	5,05%	-0,07%
Cardiovascular death	8,55%	8,18%	0,37%
cardiovascular events	22,46%	22,52%	-0,06%
All cause death	14,08%	13,53%	0,55%
Non fatal stroke	4,19%	4,24%	-0,05%
Non fatal MI	4,52%	4,55%	-0,03%

Meta-analysis of all similar trials:

TrialResults-center ID	TRC3698
Trials register #	NA